USFDA concludes inspection at Ajanta Pharma’s Paithan manufacturing facility
The inspection was conducted from April 13, 2026, to April 21, 2026
United States Food and Drug Administration (USFDA) has concluded inspection at Ajanta Pharma’s manufacturing facility at Paithan, in Maharashtra. The inspection was conducted from April 13, 2026, to April 21, 2026, and closed with the issuance of Form-483 with 5 observations. The Company will respond to the US FDA within the stipulated timeline.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
